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There is considerable concern that malaria parasites are starting to evolve resistance to the current generation of antimalarial
drugs, the artemisinin-based combination therapies (ACTs). We use pharmacological modeling to investigate changes in ACT
effectiveness likely to occur if current regimens are extended from 3 to 5 days or, alternatively, given twice daily over 3 days. We
show that the pharmacology of artemisinins allows both regimen changes to substantially increase the artemisinin killing rate.
Malaria patients rarely contain more than 1012 parasites, while the standard dosing regimens allow approximately 1 in 1010 para-
sites to survive artemisinin treatment. Parasite survival falls dramatically, to around 1 in 1017 parasites if the dose is extended or
split; theoretically, this increase in drug killing appears to be more than sufficient to restore failing ACT efficacy. One of the most
widely used dosing regimens, artemether-lumefantrine, already successfully employs a twice-daily dosing regimen, and we argue
that twice-daily dosing should be incorporated into all ACT regimen design considerations as a simple and effective way of en-
suring the continued long-term effectiveness of ACTs.
Artemisinin-based combination therapies (ACTs) are theglobal first-line treatments for the most serious of the human
malaria species, Plasmodium falciparum. Recent reports that arte-
misinin resistance may be evolving in Southeast Asia have caused
considerable alarm over our ability to both treat and control this
lethal infection (1–4). Artemisinin resistance alone has little clin-
ical impact, provided its partner drug within the ACT remains
effective, but as resistance to these partner drugs starts to evolve,
more pressure is placed on the artemisinin component to ensure
that the ACT remains effective. One option to restore treatment
efficacy is to replace a failing ACT with one based on a different,
effective partner drug. However, the development of new partner
drugs and their implementation as first-line therapy are a long and
expensive process (5). An attractive alternative is to improve the
stewardship of existing ACTs and to restore or maintain their
clinical effectiveness through improvements in their deployment
regimens.
One obvious regimen change is to simply increase the total
dose given to patients, as has historically been done with several
antimalarial drugs (e.g., chloroquine) (6). However, this ap-
proach means that patients potentially receive dosages exceeding
the target range recommended by theWorldHealth Organization
(WHO), thereby raising concerns over drug safety and potential
toxicity. An alternative strategy is to maintain the same daily dose
but extend the regimen, e.g., from 3 to 5 days. As with increasing
the daily dose, extended regimens may lead to drug safety con-
cerns if the drug is known to accumulate in the physiological com-
partment, where it elicits adverse effects. However, some antima-
larial drugs, such as piperaquine (PPQ), are rapidly distributed
away from the central (adverse-effect) compartment, thus reduc-
ing its accumulation and hence potential toxicity. These pro-
longed treatments have been considered, for example, to over-
come multidrug resistance in malaria in the Greater Mekong
Subregion (1). A final, potentially highly effective strategy has
emerged from our recent investigations of antimalarial pharma-
cokinetic (PK)/pharmacodynamic (PD) models (7–9) and from a
patient-based pharmacological analysis (10). It involves main-
taining the standard 3-day regimen but administering the drugs in
twice-daily doses. This strategy of twice-daily dosingwas shown to
be effective in vitro following artemisinin treatment (11) and is
already used for the ACT artemether-lumefantrine (AL) (12, 13).
These strategies are applicable to all ACTs, but here we exam-
ine the specific case of dihydroartemisinin (DHA)-PPQ, a widely
used fixed-dose ACT currently given in three consecutive daily
doses for the treatment of uncomplicated P. falciparum malaria.
We selected this as a model drug because several recent analyses
have suggested an increased risk of treatment failure with the
current DHA-PPQ regimen, e.g., a population PK study (14),
an observational cohort study (15), a pooled meta-analysis in-
vestigating over 7,000 patients (16), and predictions from a
pharmacological model (9). The choice of DHA-PPQ also al-
lowed us to use a range of one-, two- and three-compartment
PK calibrations that cover the PK characteristics of most cur-
rent antimalarial drugs. We calibrated parasite resistance levels
to generate drug failure rates ranging from 2 to 35%. These are
higher than those currently being observed in the field, but it is
important to emphasize that DHA-PPQ is used here as a theo-
retical example, as our approach is most useful in modeling a
future scenario where drug failure rates have reached signifi-
cant levels and when a drug policy change is needed.
This study used a PK/PD simulation approach to quantify and
Received 27 February 2015 Returned for modification 12 June 2015
Accepted 22 July 2015
Accepted manuscript posted online 3 August 2015
Citation Kay K, Hodel EM, Hastings IM. 2015. Altering antimalarial drug regimens
may dramatically enhance and restore drug effectiveness. Antimicrob Agents
Chemother 59:6419–6427. doi:10.1128/AAC.00482-15.
Address correspondence to Katherine Kay, Katherine.Kay@LSTMed.ac.uk.
Supplemental material for this article may be found at http://dx.doi.org/10.1128
/AAC.00482-15.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.
doi:10.1128/AAC.00482-15
The authors have paid a fee to allow immediate free access to this article.
October 2015 Volume 59 Number 10 aac.asm.org 6419Antimicrobial Agents and Chemotherapy
compare the abilities of four alternative regimens to restore the
clinical effectiveness of DHA-PPQ in the face of potential drug
resistance.Details of the dosing regimens are summarized inTable
1. We investigated the standard dosing regimen, i.e., SR3/3, the
current standard regimen (SR) of DHA-PPQ given as three daily
doses (note that the subscript 3/3 indicates 3 doses over 3 days).
We also investigated two extended (indicated by the prefix e)
5-day regimens, i.e., eSTD5/5, an extended regimen with the same
total dose (STD) as the SR (consequently, the amount of drug
given per day was reduced to 3/5  60% of that of the SR), and
eITD5/5, an extended regimen with an increased total dose (ITD).
The same daily dose is given as in the current SR (i.e., in SR3/3),
so increasing the duration to five daily doses resulted in a
5/3 1.67-fold (or 67%) increase in the total dose.
In addition, we investigated two 3-day split (indicated by the
prefix s)-dose regimens where six doses are equally spread over 3
days at 12-h intervals, i.e., sSTD6/3, a split twice-daily regimen
using the STD as the SR (each twice-daily dose therefore contains
half the daily drug dosage of the SR), and sITD6/3, a split twice-
daily regimenwith an ITD (each twice-daily dose is the same as the
daily dose in the current regimen [i.e., SR3/3], resulting in patients
receiving twice the total dosage given in the current SR).
Current antimalarial regimens for uncomplicated malaria last
a maximum of 3 days (17), and it is generally believed that adher-
ence will fall if the regimens last longer than 7 days (17). Adher-
ence is a complex topic (see theDiscussion), so, for illustration, we
examined a simple scenario in which poorly adherent (indicated
by the prefix pa) patients take only three of the recommend five
doses in the eSTD5/5 extended regimen, i.e., pa[eSTD5/5]. This
regimen has reduced daily doses of DHA-PPQ (see above), so
these patients consequently receive only 3/5 of the current recom-
mended total.
Poor adherence to eITD5/5, defined as patients taking only
three of the required five doses, is equivalent to patients taking the
standard 3-day regimen (see the description of eITD5/5 above);
hence pa[eITD5/5]' SR3/3.
MATERIALS AND METHODS
PK/PD model. Drug treatment was simulated by using a PK/PD mecha-
nism-based modeling methodology as described in previous publications
onmalaria drug treatment (7–9, 18, 19). Themodel tracked parasite num-
bers as a function of parasite growth and changing drug concentrations.
The PK parameters do not alter in the simulations (for example, there are
no dosage-induced changes in the elimination rate).
PD component. The PD component of the model, i.e., P. falciparum
sensitivity toDHA and PPQ, followedMichaelis-Menten kinetics andwas
modeled by using the calibrations described previously (7) and validated
against field observations. For DHA, themean slope factor (n) was 4, with
a coefficient of variation (CV) of 0.3, the mean 50% inhibitory concen-
tration (IC50) was 0.009 mg/liter (CV  1.17), and the mean killing rate
(Vmax) was 27.6/day or 1.15/h (CV 0.30). For PPQ, n 6 (CV 0.30),
IC50  0.088 mg/liter (CV  0.30), and Vmax  3.45/day (CV  0.30).
Note that the IC50 of PPQ lies toward the upper range of reported values,
and its implications for failure rates in simulations based on two- and
three-compartment PK models are discussed above.
PK component of DHA. The PK component of DHA was also cali-
brated and validated previously (7). The mean central volume of distri-
bution (Vc) was 1.49 liters/kg (CV 0.48), and themean elimination rate
constant (k) was 19.8/day (CV  0.23), the latter being equivalent to a
half-life of ln(2)/19.8 0.035 day or 0.85 h.
PK component of PPQ. There are several published estimates of PPQ
PK parameters, but the structural models differ in the number of com-
partments required to describe the PK profile, some using two compart-
ments (20–22) and some using three (14, 23, 24). This study concentrated
on the results of a previously calibrated and validated one-compartment
model (7) plus three calibrations of the two-compartment PK models
(20–22) and three calibrations of the three-compartment PKmodels (14,
23, 24). Details are as follows.
One-compartment model for PPQ. The one-compartment PKmodel
for PPQ used Vc 150 liters/kg (CV 0.42) (25) and k 0.03/day (CV
0.54) (21). Using the methods described by Winter and Hastings (7), this
calibration (calibration 1) predicted amaximal drug concentration (Cmax) of
0.12 ng/ml following an 18-mg/kg single PPQ dose, which was within the
range reported by Chinh et al. (25).
Two-compartment models for PPQ. The methodology required to
simulate a two-compartment PKmodel, assuming first-order absorption,
linear elimination, and multiple doses (without lag time), was described
previously in an appendix by Kay and Hastings (8) and by Bertrand and
Mentré (26). The two-compartment PK model was initially calibrated by
using data from a recently published PK study with DHA-PPQ in Cam-
bodia (20) (calibration 2a) and then with published PK studies with Thai
patients (22) (calibration 2b) andCambodian adults (21) (calibration 2c).
The mean PK parameters, their distributions, the typical patient body
weight, and the original dosing regimen (used in the PK studies) are given
in Table 2. To validate each calibration, the predicted Cmax and time to
Cmax (tmax) were simulated and compared with the observed values from
the original publications as follows: calibration 2a, Fig. 6 and raw data in
reference 20; calibration 2b, Fig. 5 in reference 22; calibration 2c, Fig. 3 in
reference 21.
Three-compartment models for PPQ. The methodology required to
simulate a three-compartment PKmodel with first-order absorption, lin-
ear elimination, and multiple doses (without lag time) was described by
Bertrand andMentré (see equation 1.72 in reference 26). The three-com-
partment PKmodel was calibrated by using data from three recently pub-
lished PK studies of DHA-PPQ in pregnant and nonpregnant Thai
women (23) (calibration 3a), Burkinabe children (14) (calibration 3b),
and pregnant and nonpregnant Sudanese women (24) (calibration 3c).
TABLE 1 DHA-PPQ dosing regimens and a poor-adherence scenario investigated in this study
Regimena Dosing interval
DHA/PPQ amt (mg/kg)
Single dose Total dose
SR3/3 (standard regimen) Once daily for 3 days 4/18 12/54
eSTD5/5 (extended regimen) Once daily for 5 days 2.4/10.8 12/54
pa[eSTD5/5] (eSTD5/5 with poor adherence) Once daily for 3 days (doses four and five missed) 2.4/10.8 7.2/32.4
eITD5/5 (increased and extended regimen) Once daily for 5 days 4/18 20/90
sSTD6/3 (split SR3/3) Twice daily for 3 days 2/9 12/54
sITD6/3 (twice SR3/3) Twice daily for 3 days 4/18 24/108
a The DHA-PPQ ratio in the combination is 1:4.5, which is the ratio of the target dose recommended by the WHO. For the dosing regimens containing the commercially available
fixed-dose combination (1:8 ratio), see Table S2 in the supplemental material.
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The mean PK parameters, their distributions, the typical patient body
weight, and the original dosing regimen (used in the PK studies) are
shown in Table 2. To validate each calibration, the predicted Cmax and
tmax were simulated and compared with the observed values from the
original publications as follows: calibration 3a, Fig. 3a in reference 23;
calibration 3b, Fig. 3 in reference 14; calibration 3c, Fig. 6 in reference 24.
Ratio of DHA to PPQ in the simulations. An important operational
point, specific to DHA-PPQ, is that the WHO currently recommends
dosing with a DHA-to-PPQ ratio of 1:4.5 (17). This ratio means that
patients treated with the coformulated drug combination get the appro-
priate amount of each drug. However, for historical reasons, the commer-
cially available coformulations routinely used as first-line therapies in
countries where malaria is endemic contain a DHA-to-PPQ ratio of 1:8
(27). The component with the narrower therapeutic window, in this case,
PPQ, dictates the upper dosage of the combination that can be given to
patients, so treatment using these coformulations systematically gives pa-
tients less than the recommend 4-mg/kg dosage of DHA. Both the recom-
mended ratio and the actual coformulated drug ratio were checked for
putative regimen changes.
Simulations. The PK/PD models were each used to simulate 5,000
infected patients followed up for 63 days after treatment to determine the
“true” cure rate, “apparent” cure rate, and parasite clearance time (PCT)
of each regimen (see Table S1 in the supplementalmaterial). The true cure
rate was defined as the proportion of patients whose infections were com-
pletely cleared. The apparent or observed cure rate was defined as the
proportion of patients whose infections were below the limit of micro-
scopic detection, defined as 108 parasites, on days 28, 42, and 63 posttreat-
ment. The apparent cure rate is themost likely measure of effectiveness to
be reported from clinical trials. The PCT is the time taken for a patient’s
infection to drop to undetectable levels, also defined as 108 parasites.
Individual PK/PD parameters were sampled from a normal distribution
for parameters when the CV was less than 50% and from a log-normal
distribution when the CV was 50% (see reference 8 for details of the
latter). Each patient was simulated six times to receive each of the five
dosing regimens and the poor-adherence scenario. Note that we do not
consider transmission intensity, as we assumed all of the individuals in the
simulation to be infected with a single malaria clone. This provides the
treatment outcome “per clone” and avoids themore complicated analyses
required when simulating multiclonal infections (see reference 28 for
more information). Details of the dosing regimens are given in Table 1
and were based either on the target dose recommended by the WHO,
where the DHA-to-PPQ ratio is 4:18 1:4.5 (17) or on the commercially
available coformulation, where the DHA-to-PPQ ratio is 1:8 (27) (see the
dosing regimens in Table S2 and the results in Table S3 and Fig. S1 in the
supplemental material).
RESULTS
A one-compartment model clearly fails to capture the concentra-
tion-over-time profile of PPQ, but it does reproduce observed
clinical failure rates (Fig. 2 in reference 9 compared to Table 6 and
Fig. 4 in reference 16). This one-compartmentmodelwas useful in
developing the methodological underpinning for antimalarial
PK/PD modeling and, although pharmacologically rather crude,
did allow the reliable replication of observed field and clinical data
(e.g., reference 7). A wider range of failure rates was predicted for
TABLE 2 Mean PPQ PK parameters for the two- and three-compartment model calibrationsa
Parameter
Value for following calibration (reference):
2a (20) 2b (22) 2c (21) 3a (23) 3b (14) 3c (24)
Study population Cambodian Burmese and Karen Cambodian Thai Burkinabe Sudanese
Study size Adults and children
(n 60)
Adults (n 87) and
children (n 11)
Adults (n 38) Pregnant (n 24) and
nonpregnant (n 24)
women
Children (n 236) Pregnant (n 24) and
nonpregnant (n 24)
women
D (mg/kg) 2.9/22.9 at 0 and 24 h,
1.9/15.2 at 48 h
7/55 split into 3 or 4
doses
1.7/13.6 at 0, 6, 24,
and 32 h
2.1/17 at 0, 24, and 48 h 12.4/8.8 at 0, 24,
and 48 h
2.3/18.1 at 0, 6, 24, and
32 h
Typical BW (kg) 42 48 47 48 18 53
CL (liters/day) 108 · BW0.75 (1.01) 1,584 · [1 0.0262 ·
(BW 48)] (0.42)
— 939.1d (0.71) 10.0 (0.38) 12.1g (0.45)
ka (day
1) 11.2b (2.17) 17.2 (1.68) 1.99 (1.08) 3.5e (1.08) 1.99f (1.08) 1.99f (1.08)
k (day1) — — 1.4 (0.78) — — —
Q1 (liters/kg/day) 69.7 (1.01) 65.5 (0.85) — 106.8
d (1.02) 17.5 (5.32) 10.8g (0.94)
Q2 (liters/kg/day) — — — 52.0
d (0.70) 14.4 (0.66) 119.5g (0.51)
k12 (day
1) — — 4.6 (0.57) — — —
k21 (day
1) — — 0.1 (1.31) — — —
Vc (liters/kg) 346.0 (0.93) 8,660 · [1 0.0273 ·
(BW 48)]/BW
(1.01)
14.5 (0.46) 57.6d (0.86) 13.7 (2.16) 34.3 (0.53)
Vp1 (liters/kg) 443.0 (1.70) 500.0 (0.50) 559.5
c 92.5 (1.21) 14.1 (2.15) 300.0 (0.60)
Vp2 (liters/kg) — — — 654.2 (0.65) 185.6 (0.51) 141.9 (0.81)
a BW, body weight of the typical patient in the original study; D, dose of DHA and PPQ administered to the typical patient in the original study; CL, clearance; ka, absorption rate;
k, elimination rate (k CL/Vc); Q1, intercompartmental clearance between the central compartment and peripheral compartment 1; Q2, intercompartmental clearance between the
central compartment and peripheral compartment 2; k12, rate of transfer from the central compartment to the peripheral compartment (k12 Q1/Vc); k12, rate of transfer from the
peripheral compartment to the central compartment (k21 Q1/Vp1); Vc, central volume of distribution; Vp1, volume of distribution in peripheral compartment 1; Vp2, volume of
distribution in peripheral compartment 2. The CV of each value is shown in parentheses., no data or not applicable.
b The value was 50% lower than that in the original study (20).
c Calculated from the steady-state volume of distribution (Vss), i.e., Vp1 Vss Vc, and reported only for completeness (Vp1 is not required for calculations, and the CV was not
given in the original study).
d CL, Q1, Q2, and Vc were 35, 50, 10, and 10%, respectively, lower than in the original study.
e Value taken from reference 21 and 75% higher than that in the original study.
f Value taken from reference 21.
g CL, Q1, and Q2 were 40, 50, and 25% lower, respectively, than in the original study.
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two- and three-compartment models using the SR (the SR3/3 col-
umns in Fig. 1), and this is a consequence of using a PPQ IC50 in
the upper range of observed values (29). Estimates of IC50s vary
considerably between studies, and while the in vitro measures of
IC50 may not necessarily represent the in vivo value, an IC50 of
0.088 mg/liter was used previously (7) as an appropriate calibra-
tion for a one-compartment model. PPQ concentrations decline
much faster in the more realistic two- or three-compartment
models, so the PPQ IC50 should, in principle, be reduced to allow
more killing in the shorter time period when the drug is present in
the central compartment, where killing occurs.We chose to retain
the IC50 of 0.088 mg/liter in these two- and three-compartment
models because this is a theoretical example that can be most
usefully applied to future situations in which clinical efficacy has
declined. It was also deemed preferable to maintain the high IC50
to simulate a situation in which drug resistance has started to
evolve and cure rates are declining (30, 31). The current SR, SR3/3,
gave cure rates of 65 to 96% for two- and three-compartment
models (see Table S1 in the supplemental material), which span
the threshold of 90%, the point at which the WHO states that the
drug should be replaced (32). This range of cure rates was ideal to
achieve the primary, key objective of this study, i.e., to test whether
regimen changes give consistent patterns of results over a range of
calibrations and basal drug failure rates.
The predicted cure rates and PCTs for all seven PK/PD calibra-
tions and all dosing regimens are shown in Table S1 in the supple-
mentalmaterial. Figure 1 illustrates the predicted cure rates for the
regimens based on theWHO-recommended target DHA-to-PPQ
dose ratio of 1:4.5, i.e., DHA at 4 mg/kg/day and PPQ at 18 mg/
kg/day (17).
The cure rates of the novel regimens (assuming that the pa-
tients are fully adherent) were very high (97%; see Table S1 in
the supplemental material) for the one-compartment calibration
(7) butmuchmore variable for themore biologically realistic two-
and three-compartmentmodels. Extending the regimens from the
standard 3-day regimen (SR3/3) to either of the 5-day regimens
(eSTD5/5 and eITD5/5) reduced estimates of failure rates in the
model across all of the calibrations. This was true even when the
failure rates were particularly low; for example, the 2% failure rate
for SR3/3 in calibration 1 was cut to 0.6% (eSTD5/5) and 0.3%
(eITD5/5), representing at least a 3-fold reduction in the failure
rate. Both of the split twice-daily dosing regimens (sSTD6/3 and
sITD6/3) also dramatically reduced treatment failure rates (Fig. 1).
Notably, sITD6/3 gave the highest cure rates for all of the simulated
regimens (92 to 99.9% cure rates across all calibrations, dark blue
columns in Fig. 1), while sSTD6/3 consistently performed better
than the 5-day eSTD5/5 regimen (gray versus green columns in Fig.
1) and had cure rates broadly similar to those of the eITD5/5 reg-
imen (gray versus pale blue columns in Fig. 1). These results were
obtained when using theWHO’s recommended “optimal” DHA-
to-PPQ ratio; repeating these calculations with the DHA-to-PPQ
ratio of the commercially available coformulation gave qualita-
tively near-identical results (see Table S2 and Fig. S1 in the sup-
plemental material). The quantitative differences were a relative
reduction in cure rates of 1 to 14% compared with the equivalent
result obtainedwith theWHO-recommended ratio (note that this
is a relative reduction).
Poor adherence to the 5-day regimenwas defined here asmiss-
ing the last two doses, and it dramatically reduced treatment cure
rates. In the case of poor adherence to eITD5/5, the cure rates were,
by definition, those of the SR3/3 (pale blue versus red columns in
Fig. 1). Poor adherence to eSTD5/5 gave the model output pre-
sented in pa[eSTD5/5] (green versus orange columns in Fig. 1); i.e.,
cure rates were reduced by approximately 7% in calibration 1, 35
to 50% in calibration 2, and 8 to 38% in calibration 3 (again, note
that this is a relative reduction.
The variation in Cmax associated with changing the recom-
mended SR3/3 regimen to eITD5/5, sSTD6/3, or sITD6/3 was esti-
mated for the two- and three-compartment model calibrations
(Fig. 2). The median Cmax increase obtained with the simulated
eITD5/5 regimen lies in the range of 13 to 63% above that of the SR
(eITD5/5: SR3/3 in Fig. 2). ThemedianCmax increase obtained with
the simulated sITD6/3 regimen lies in the range of 75 to 99% above
that of the SR (sITD6/3: SR3/3 in Fig. 2). As expected, splitting the
total dose into six doses did reduce the median Cmax; the decrease
was between 1 and 12% (sSTD6/3: SR3/3 in Fig. 2), depending on
the PK model structure and the model calibration. Figure 2 sum-
marizes themodel output from individual simulated patients, and
it is important to note the considerable interpatient variability
around these median changes in Cmax (see the Discussion).
DISCUSSION
A fundamental medical principle is that the physician should
“above all, do no harm” (33). Consequently, we first discuss the
implications of the regimen changes for drug safety before turning
to our primary concern of how they change drug efficacy. Adverse
drug effects may be driven by different mechanisms, depending
on the drug. The principal safety concerns relate to the maximal
drug concentration occurring in a patient after treatment (i.e.,
Cmax), the total drug exposure (quantified as the area under the
concentration-over-time curve), or an average drug concentra-
tion over a certain time period after treatment. In the specific
example of PPQ, safety concerns relate mainly to Cmax, so the
changes in Cmax were estimated for the two- and three-compart-
ment calibrations (Fig. 2). Splitting the current 3-day regimen
FIG 1 The percentage of individuals predicted to be cured by five DHA-PPQ
dosing regimens and one poor-adherence scenario. Cure rates were estimated
across seven different PK calibrations for PPQ. The regimens and poor-adher-
ence scenario are described in the text and summarized in Table 1. The PK
calibrations are as follows (see the text for more details). Calibration 1 is the
one-compartment PKmodel described in reference 7. Calibrations 2a to 2c are
two-compartmentmodels based ondata from references 20 to 22, respectively.
Calibrations 3a to 3c are three-compartment models based on data from ref-
erences 14, 23, and 24, respectively.
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(SR3/3) into twice-daily dosing (sSTD6/3) maintains the STD, so
Fig. 2 shows the expected result, i.e., that a patient’sCmaxwill be no
higher and probably much lower than with the current SR. In
contrast, extending the SR3/3 regimen over 5 days (eITD5/5) does
increase the total dose and sowill inevitably increase the PPQCmax
by a factor of up to 5/3 1.67. Similarly, giving the standard dose
twice daily (sITD6/3) doubles the total amount of PPQ given, with
a consequent increase in the patient’s Cmax. Importantly, Fig. 2
reveals considerable interpatient variability around these changes
in the median Cmax. This variability arises because PPQ is distrib-
uted away from the central compartment into one or more pe-
ripheral compartments. Patients who slowly transfer PPQ from
the central compartment to a peripheral compartment(s) will
tend to accumulate PPQ in the central compartment over subse-
quent doses and will have higher Cmax ratios. Conversely, patients
with a high transfer rate will accumulate less PPQ between doses
and so will have much lower Cmax ratios. The differences in the
median Cmaxs observed in the different calibrations may be ex-
plained in the same way; i.e., calibrations where transfer from the
central compartment is relatively slow tend to accumulate PPQ
and have larger median Cmax changes. As a caveat, it is impossible
to estimate a definitive value for the changes in Cmax associated
with regimen changes without applying more sophisticated ab-
sorption/distribution models to the raw PK data, although we
believe our estimated changes in Cmax are qualitatively fairly ac-
curate because any PK approximation(s) will apply to all of the
doses given in the regimen.
In the specific case of DHA-PPQ, safety concerns focus on the
PPQ Cmaxs, which are associated with QTc prolongation (heart
rhythm-correctedQT interval, a prolongation of the time between
the start of the Q wave and the end of the T wave in the heartbeat
cycle). This occurs in a dose-dependent manner determined by
the Cmax in the central compartment (for recent data, see refer-
ences 34 and 35). There is currently no consensus on how to trans-
late a PPQ Cmax to a risk of QTc prolongation, but presenting the
likely size and variability of the Cmax increases associated with
regimen changes (Fig. 2) serves two purposes. First, it proves a
point of principle that Cmax changes do not scale with changes in
the total dose. For example, the total PPQ intake increased by a
factor of 5/3 1.67 in eITD5/5 but theCmax increased by amedian
factor of around 1.1 to 1.5, depending on the PK calibration (Fig.
2), and this point needs to be recognized when regimen changes
are being evaluated in terms of potential safety. Second, these
distributions of Cmax provide a resource to interpret any future
estimations of the relationship between Cmax and QTc. The im-
portant policy implications of these results are that (i) proposals to
extend the duration of DHA-PPQ regimens will not drive an in-
crease in the median Cmax proportional to the changes in the total
dosage, but (ii) there will be considerable interpatient variation
around this median so that extended regimens will almost cer-
tainly elicit significant Cmax increases in a minority of patients.
These concerns over safety need to be balanced against changes
in drug effectiveness. The key result is that changing the current
standard once-per-day 3-day regimen to any of the proposed al-
ternative regimens predicted dramatically improved drug cure
rates (Fig. 1; see Table S1 in the supplemental material) and that
these simulated results were consistent across all seven PK calibra-
tions and for treatment with drugs containing either the WHO-
recommended or commercially available DHA-to-PPQ ratio (see
the supplemental material). Even in calibration 1, where true cure
rates were already high (97%), changing to 5-day regimens was
predicted to reduced failure rates at least 3-fold. As might be ex-
pected, treatment with the optimal WHO-recommended DHA-
to-PPQ ratio improved simulated cure rates by up to 14% com-
pared to the equivalent commercial coformulated regimen
containing a lower proportion of DHA. For example, calibration
2bpredicted a cure rate of 67.5% (seeTable S1 in the supplemental
material) when patients were given the current SR (SR3/3) con-
forming to the WHO-recommended DHA-to-PPQ ratio and
58.1% when the DHA-to-PPQ ratio was reduced to match that of
FIG 2 Changes in the PPQ Cmax that are predicted to occur as regimens are either extended from 3 to 5 days or changed to twice daily for 3 days. Changes are
plotted as the ratio of the Cmax predicted for the new regimen to the Cmax predicted for the same patient following the current SR (i.e., SR3/3). The red dashed
reference line shows a ratio of 1, which indicates no change in the Cmax associated with a regimen change, and the box plots show the ratios obtained for 5,000
individual patients. The regimens are detailed in Table 1 and explained in the text, but briefly, the left panel shows the change associated with extending the
current regimen from 3 to 5 days, the center panel shows the change associated with splitting the current dose into two daily doses andmaintaining the STD, and
the right panel shows the change associated with giving the current dose twice daily, which obviously results in patients being given twice the existing dosage. The
Cmax changes were estimated across six PK calibrations as described in the text and in the legend to Fig. 1.
Enhancing and Restoring Antimalarial Effectiveness
October 2015 Volume 59 Number 10 aac.asm.org 6423Antimicrobial Agents and Chemotherapy
the commercially available coformulation (see Table S2 in the
supplemental material), hence the 14% relative reduction.
The four proposed regimen changes all greatly increased the
cure rate, but each had practical advantages and disadvantages.
The eSTD5/5 regimen was effective without drasticCmax increases,
but our simulations suggest that poor adherence has the potential
to substantially reduce the efficacy of this regimen; Fig. 1 shows
the drop in cure rates that would occur if only three of the five
daily doses were taken (i.e., comparing the green eSTD5/5 column
with the orange pa[eSTD5/5] column). The sITD6/3 regimen raises
safety concerns; the total dose is doubled and theCmax is increased
considerably in all of the parameterizations (Fig. 2). We believe
these practical drawbacks are sufficiently serious to preclude the
use of these two regimens as first-line therapies in most clinical
situations, although readers are entitled to make up their own
minds. The remaining two regimens, eITD5/5 and sSTD6/3, appear
more plausible as first-line therapies. The extended eITD5/5 regi-
men has two main potential drawbacks: the possible impact of
poor adherence to a 5-day regimen (i.e., comparing the pale blue
eITD5/5 column with the red SR3/3 column in Fig. 1) and the 67%
increase in the total dose and the subsequent increases in Cmax
(shown in Fig. 2). In contrast, the sSTD6/3 regimen is the least
critical in terms of safety concerns; the total dose stays the same, so
the PPQ Cmax is reduced (Fig. 2). Its only potential drawback may
be poorer adherence to a twice-daily regimen. A systematic inves-
tigation of the impact of poor adherence would be a complex task
(36, 37). There are various patterns of nonadherence, depending
on whether doses are missed and/or delayed, and operationally,
this all occurs in a context in which people are dosed according to
age or weight bands, which further inflates the variation in the
drug dosages actually taken by patients. An example of the re-
quired approach can be found in reference 9, but it is a complex
analysis and this study focuses on a more specific research ques-
tion, i.e., the extent to which modifying regimens can help offset
the evolution of resistance. A clear next stepwould be to utilize the
predictions made herein to inform the design of empirical studies
from which more specific recommendations can be derived. One
“problem” at present is that all ACTs appear to be currently highly
effective (but see reference 15), and it is extremely difficult to
statistically identify a regimen that improves the cure rate from,
for example, 96 to 98% (even though the failure rate has been
halved from4 to 2%).Our objective has therefore been 2-fold, first
to identify robust regimens that are theoretically capable of delay-
ing and offsetting the threats posed by drug resistance and second
to establish a pharmacological framework to explore dosing op-
tions to be explored if or when drug failure rates start to rise to
unacceptable levels.
There is a precedent for the split-dose strategy for malaria
treatment. AL is possibly the most widely used antimalarial drug
and is given as a twice-per-day regimen for 3 days. This regimen
was designed because lumefantrine absorption from the gut satu-
rates at high drug levels so a strategy of giving smaller amounts of
lumefantrine more frequently increases the total amount of drug
absorbed (38), hence the choice of twice-daily dosing. Interest-
ingly, adherence to this twice-daily regimen appears not to be
markedly reduced (36). The presence of an existing twice-daily
antimalarial regimen would also help the deployment of new
twice-daily regimens of other antimalarial drugs. Most clinics and
private health care providers stock a range of antimalarial drugs,
and poor adherence can arise because of confusion among pa-
tients or health care providers about exactly how a drug is to be
taken (39). Consistency between the various ACT regimens (i.e., if
all antimalarials were to be taken twice daily over 3 days) may
therefore help reduce confusion and improve overall adherence to
all antimalarial regimens.
It is relatively easy to explain why increasing the duration of
treatment or splitting a 3-day regimen with daily doses into a
3-day regimen with twice-daily dosing dramatically increases
overall ACT effectiveness. This arises because treatment with ar-
temisinins follows the law of diminishing returns identified and
discussed briefly by us (see Fig. 5 in reference 40). This effect is
illustrated in Fig. 3, where the top panel shows DHA concentra-
tions after treatment with either the standard 4-mg/kg dose given
in the current SR or a single 2-mg/kg dose given when this stan-
dard once-daily dose is split into two daily doses. The law of di-
minishing returns applies because these concentrations in the top
panel of Fig. 3 are converted into parasite killing through the Mi-
chaelis-Menten function shown in themiddle panel of Fig. 3. Kill-
ing saturates at higher drug concentrations, so the higher concen-
trations achieved by the standard dose in the top panel of Fig. 3 are
superfluous for most of the time posttreatment. This effect is
FIG 3 Why splitting DHA doses has such a large impact on overall killing.
(Top) DHA concentrations following the administration of either the stan-
dard daily dose (4 mg/kg) or half that amount, as used in the split doses, i.e., 2
mg/kg. (Middle) How the DHA concentration translates into parasite killing
(per hour) when using the standard Michaelis-Menten killing curves (e.g.,
equation 1 in reference 8) and theDHAparameters given in the text. (Bottom)
Posttreatment drug killing (per hour) by DHA, obtained by converting the
DHAconcentration profiles in the top panel into drug killing rates by using the
function in the middle panel.
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shown in the bottom panel of Fig. 3, which shows killing rates
posttreatment. As shown, halving the dose has only a small impact
on the total killing, measured as the area under the killing curve.
This effect can be quantified “intuitively” by noting that the stan-
dard dose persists at active killing concentrations for around 7 h
posttreatment (Fig. 3, bottom panel). Doubling the dose would,
by definition, shift this curve to the right by oneDHAhalf-life, i.e.,
by 0.85 h. This would translate into an increase in total killing by a
factor of around (7  0.85)/7  1.12, and this 12% increase in
total killing is much less than the factor of 2 by which the dosage
was increased. More relevant to our regimens is the halving of the
dose; this shifts the killing curve to the left, resulting in a decrease
in total killing of around (7 to 0.85)/7 6.15/7 0.88, and again,
this 12% reduction in killing is much less than the 2-fold reduc-
tion in the amount of drug used. The 2-mg/kg dose is given twice
per day, so the increase in killing compared to that of a standard
4-mg/kg single daily dose is by a factor of 2 0.88 1.76 or 76%
per day. More precise calculations can be made by obtaining the
area under the drug killing curve (Fig. 3, bottom panel) by simple
integration. The values are 7.94 killing days for the standard dose
and 6.98 killing days for the split dose. Splitting the three daily
4-mg/kg doses into six twice-daily 2-mg/kg doses dramatically
improves the total DHA killing because, critically, these measure-
ments are on an exponential scale (i.e., the areas under the drug
killing curves are the integration terms in the appendix of refer-
ence 18 and equation 16 of reference 8). The total amount of
parasite killing byDHA in a 3-day standard ACT regimen is there-
fore exp(3  7.94)  2.2  1010, and in the 3-day split dose
regimen, it is exp(6  6.98)  1.54  1018. The same effect ex-
plains the increased efficacy of the 5-day extended-dosing regi-
men, whose DHA killing can be calculated as exp(5  7.94) 
1.7  1017. Technically, these drug killing rates are incorporated
into PK/PDmodeling by using their reciprocals to predict parasite
survival (hence the negative signs associated with the integration
terms in the appendix of reference 18 and equation 16 of reference
8). In plain English, this states that 1 parasite in 2.2  1010 is
predicted to survive DHA treatment in the SR and approximately
1 in 1.54 1018 or 1 in 1.7 1017 is predicted to survive the split
or extended regimen, respectively.
This is a remarkable result, as it suggests that the simple expe-
dient of splitting the DHA dose can increase its overall killing
within an ACT by a factor of 108, an increase that appears easily
sufficient to restore efficacy to failing ACTs. These results are con-
sistent with early clinical trials showing that 3-day treatments with
artemisinin monotherapies had high failure rates and that regi-
mens required five to seven daily doses to be effective (41). These
observations can therefore now be easily explained by noting that
a symptomatic malaria patient typically contains 1010 to 1012 par-
asites. The 3-day SR is estimated (see above) to have the potential
to kill approximately 1010 parasites, so is unlikely to clear all of the
parasites in the patient. Conversely, the split regimens and ex-
tended 5-day regimens have the potential to kill approximately
1018 and 1017 parasites, respectively, and so should reliably clear
most infections. These are “average” killing rates, and the large
variability associated with DHA PK/PD (see Materials and Meth-
ods) introduces substantial variation into the DHA killing rates
and explains why split or extended regimens do not cure all infec-
tions. In addition, the stage specificity of artemisinin (i.e., the
extent of drug action depends on the exact stage of the parasites in
their intraerythrocytic life cycle) also introduces variation into the
overall killing rates, although it is much less than that introduced
by PK/PD variation. This increased killing is also less likely to
allow spontaneous new resistance mutations to survive treatment
and enter the parasite population, thereby extending the ACT’s
life span (42).
These results for extended and split regimens will also apply to
ACTs containing other artemisinin derivatives such as artesunate
and artemether. These compounds are rapidly converted into
their activemetabolite DHA, so the PKs are functionally very sim-
ilar. The results are also generalizable to all of the current partner
drugs.We focused onDHA-PPQas a specific example because it is
the ACT considered most at risk of currently failing and also be-
cause it allowed us to investigate the consistency of PPQ results
across one-, two-, and three-compartment PKmodels. All partner
drugs are believed to follow one of these structural models, so the
consistency of results across models and calibrations suggests that
the results are robust (and can be easily tested for individual part-
ner drugs by different calibrations of the methodology described
herein). Note that, as explained above, regimen changes improve
therapeutic outcomes primarily by increasing artemisinin killing.
The total killing by partner drugs is relatively unaffected by the
exact dosing schedule during the first 3 to 5 days; they typically
have much longer half-lives.
These types of PK/PD analyses are valuable precursors to, but
cannot replace, the clinical trials that serve as the gold standard
upon which policy decisions will be made. However, clinical trials
of drug effectiveness are time-consuming and expensive, and re-
searchers cannot ethically knowingly administer subtherapeutic
treatment regimens to patients in order to quantify the impact of
poor adherence. Moreover, if the original regimen is still largely
effective, clinical trials cannot realistically detect the increased un-
derlying killing in the alternative regimen, as cure rates in both
treatment arms will be high and failures will often be attributable
to factors common to both arms, such as poor adherence, subop-
timal drug metabolism, or reinfection. As an example of this, Das
et al. (43) did investigate a split-dose regimen but the cure rates
were high in both arms and no differences in the parasite clearance
rate (used as a proxy for drug effectiveness) were observed. This
probably arose because parasite clearance rates are affected by a
huge number of other, nondrug factors, particularly patient im-
munity, so that, as we show in our companion paper in this issue
(44), even very large changes in drug effectiveness will be essen-
tially invisible against the dominant role of host immunity in de-
termining parasite clearance rates. Further discussion of the use-
fulness of clearance rates as a proxy for drug effectiveness can also
be found in references 44 to 46. This modeling methodology rep-
resents a fast and inexpensive approach to inform policy makers.
Moreover, the consensus methodologies are published, allowing
easy replication of the results when alternative calibrations are
provided and allowing further research into operational questions
such as their optimal dosing bands (9). In particular, splitting the
current ACT regimens into twice-daily dosing comes close to be-
ing the “holy grail” of regimen changes: it maintains the current
3-day regimens, raises no additional safety concerns, increases
artemisinin killing rates by a hugemargin, and appears to be easily
capable of restoring the effectiveness of failing ACTs. Moreover,
the underlying reasons for these properties are easily understood
intuitively and are applicable to the whole range of current ACTs,
although, importantly, the benefits are largely restricted to the
artemisinin component and cannot alter the threat posed by the
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evolution of resistance to partner drugs (e.g., see reference 47).We
believe that changes in ACT regimens should be instigated as soon
as possible to mitigate and/or avert the spread of resistance and
that this approach seems greatly preferable to themore traditional
one of first allowing resistance to arise and then attempting to find
methods of overcoming it.
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